Head to Head Analysis: Immunocore (NASDAQ:IMCR) & Nuvation Bio (NYSE:NUVB)

Immunocore (NASDAQ:IMCR – Get Free Report) and Nuvation Bio (NYSE:NUVB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Volatility and Risk

Immunocore has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.

Profitability

This table compares Immunocore and Nuvation Bio’s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Immunocore and Nuvation Bio, as reported by MarketBeat.com.

Immunocore presently has a consensus price target of $56.38, suggesting a potential upside of 76.39%. Nuvation Bio has a consensus price target of $13.22, suggesting a potential upside of 191.56%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Immunocore.

Valuation & Earnings

This table compares Immunocore and Nuvation Bio”s revenue, earnings per share (EPS) and valuation.

Immunocore has higher revenue and earnings than Nuvation Bio. Immunocore is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

84.5% of Immunocore shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Nuvation Bio beats Immunocore on 7 of the 12 factors compared between the two stocks.

About Immunocore

(Get Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

About Nuvation Bio

(Get Free Report)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.